Analyser av Calmark

Calmark: Redeye Ceases Coverage - Redeye

Redeye ceases its coverage of Calmark due to the end of the contractual period.

Redeye comments on Calmarks Q3 2022 report and recent newsflow.

Redeye leaves a short comment on Calmark on the back of changes in management.

Calmark är ett medicintekniskt bolag som utvecklar och säljer analysinstrument för patientnära diagnostik för nyfödda barn.

Redeye leaves its comments on Calmark following its Q2 report.

Redeye leaves its comments on Calmark following its Q1 report.

Redeye leaves its comments on Calmark following its Q4 report, which came in short of our expectations.

Redeye views Calmarks Q2 report as undramatic, and commercialization of its tests seems to go as planned.